PI3K/Akt/mTOR
CAS号：162635-04-3
品名：西罗莫司脂化物Temsirolimus
中文别名：替西罗莫司;西罗莫司;
英文别名：CCL-779;Rapamycin(42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate];[14C]-Temsirolimus;TeMsiroliMus(CCI-779,Torisel);TeMsiroliMus(~);rapaMycin42-esterwith3-hydroxy-2-(hydroxyMethyl)-2-Methylpropionicacid;42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin;TeMsiroliMus(Torisel);Rapamycin42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate;(1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate;
分子式：C56H87NO16
分子量：1030.29
精确质量：1029.6
Psa：241.96
UNII号：624KN6GM2T
密度：1.2g/cm3
沸点：1048.4ºC at 760mmHg
熔点：99-101ºC
闪点：587.8ºC
折射率：1.553
蒸汽压：0mmHg at 25°C
简介：Temsirolimus(CCI-779)isanintravenousdrugforthetreatmentofrenalcellcarcinoma(RCC),developedbyWyethPharmaceuticalsandapprovedbytheU.S.FoodandDrugAdministration(FDA)inlateMay2007,andwasalsoapprovedbytheEuropeanMedicinesAgency(EMEA)onNovember2007.ItisaderivativeandprodrugofsirolimusandissoldasTorisel.
